Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: A systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Winquist, Eric ^a   Waldron, Tricia ^b   Berry, Scott ^c   Ernst, D Scott ^d   Hotte, Sébastien ^e   Lukka, Himu ^e  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOGLUTETHIMIDE; ANTHRACENE DERIVATIVE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ATRASENTAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTRAMUSTINE PHOSPHATE; FLUOROURACIL; FLUTAMIDE; HYDROCORTISONE; LIAROZOLE; MEDROXYPROGESTERONE ACETATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; PREDNIMUSTINE; PREDNISONE; SURAMIN; UNINDEXED DRUG; VINBLASTINE; WARFARIN;

ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; BLOOD TOXICITY; BODY WEIGHT DISORDER; BREAST TENDERNESS; CANADA; CANCER CONTROL; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSENSUS; CONSTIPATION; DIARRHEA; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FATALITY; DRUG TREATMENT FAILURE; DYSPEPSIA; DYSPNEA; EVIDENCE BASED PRACTICE; FATIGUE; GASTROINTESTINAL TOXICITY; GYNECOMASTIA; HEADACHE; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; HYPOTENSION; INFECTION; JOINT STIFFNESS; JOINT SWELLING; LEG EDEMA; MALE; MEDLINE; META ANALYSIS; METABOLIC DISORDER; METASTASIS; NAIL DISEASE; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; RHINITIS; SEPSIS; SKIN TOXICITY; STOMATITIS; SYSTEMATIC REVIEW; THROMBOEMBOLISM; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; EVIDENCE-BASED MEDICINE; HORMONES; HUMANS; MALE; MICROTUBULES; NEOPLASM METASTASIS; ONTARIO; PROSTATIC NEOPLASMS;

EID: 33747469939     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-112     Document Type: Review

References (89)

1. Jemal A, Clegg LX, Ward E, Ries LAG, Wu X, Jamison PM: Annual report to the Nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004, 101:3-27.
2. Sharifi N, Dahut WL, Steinberg SM, Figg WD, Tarassoff C, Arlen P, Gulley JL: A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int 2005, 96:985-989.
3. Newling DW, Dennis L, Vermylen K: Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Cancer 1993, 72:3793-3798.
4. Coleman RE: Skeletal complications of malignancy. Cancer 1997, 80:1588-1594.
5. Oh WK, Kantoff PW: Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998, 160:1220-1229.
6. Browman GP, Levine MN, Mohide EA, Hayward RSA, Pritchard KI, Gafni A, Laupacis A. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995, 13:502-512.
7. Sterne JAC, Egger M, Smith GD: Investigating and dealing with publication and other biases. In Systematic Reviews in Health Care: Meta-analysis in Context Edited by: Egger M, Smith GD, Altman D. London: BMJ Publishing Group; 2001:189-208.
8. Scott WW, Gibbons RP, Johnson DE, Prout GR, Schmidt JD, Saroff J, Murphy GP: The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate. Trans Am Assoc Genitourin Surg 1977, 68:24-28.
9. Eagan RT, Hahn RG, Myers RP: Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastastic prostate cancer. Cancer Treatment Reports 1976, 60:115-117.
10. Kvols LK, Eagan RT, Myers RP: Evaluation of melphalan, ICRF-159, and hydroxyurea in metastatic prostate cancer: a preliminary report. Cancer Treatment Reports 1977, 61:311-312.
11. Murphy GP, Gibbons RP, Johnson DE, Loening SA, Prout GR, Schmidt JD, Bross DS, Chu TM, Gaeta JF, Saroff J, Scott WW: A comparison of estramustine phosphate and streptozotocin in patients with advanced prostatic carcinoma who have had extensive irradiation. J Urol 1977, 118:288-291.
12. Tejada F, Eisenberger MA, Broder LA, Cohen MH, Simon R: 5-fluorouracil versus CCNU in the treatment of metastatic prostatic cancer. Cancer Treatment Reports 1977, 61:1589-1590.
13. Chlebowski RT, Hestorff R, Sardoff L, Weiner J, Bateman JR: Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial. Cancer 1978, 42:2546-2552.
14. Schmidt JD, Scott WW, Gibbons RP, Johnson DE, Prout GR Jr, Loening SA, Soloway MS, Chu TM, Gaeta JF, Slack NH, Saroff J, Murphy GP: Comparison of procarbazine, imidazole-carboxamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate. J Urol 1979, 121:185-189.
15. Loening SA, Scott WW, deKernion J, Gibbons RP, Johnson DE, Pontes JE, Prout GR, Schmidt JD, Soloway MS, Chu TM, Gaeta JF, Slack NH, Murphy GP: A comparison of hydroxyurea, methyl-chloroethyl-cyclohexy-nitrosourea and cyclophosphamide in patients with advanced carcinoma of the prostate. J Urol 1981, 125:812-816.
16. Muss HB, Howard V, Richards F, White DR, Jackson DV, Cooper MR, Stuart JJ, Resnick MI, Brodkin R, Spurr CL: Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial. Cancer 1981, 47:1949-1953.
17. Smalley RV, Bartolucci AA, Hemstreet G, Hester M: A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. J Urol 1981, 125:191-195.
18. Soloway MS, Dekernion JB, Gibbons RP, Johnson DE, Loening SA, Pontes JE, Prout GR Jr, Schmidt JD, Scott WW, Chu TM, Gaeta JF, Slack NH, Murphy GP: Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate. J Urol 1981, 125:664-667.
19. Herr HW: Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chloroethyl-cyclohexy-nitrosourea in the treatment of metastatic prostatic cancer. J Urol 1982, 127:462-465.
20. DeWys WD, Begg CB, Brodovsky H, Creech R, Khandekar J: A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response. Prostate 1983, 4:1-11.
21. Soloway MS, Beckley S, Brady MF, Chu TM, Dekernion JB, Dhabuwala C, Gaeta JF, Gibbons RP, Loening SA, McKiel CF, McLeod DG, Pontes JE, Prout GR, Scardino PT, Schlegel JU, Schmidt JD, Scott WW, Slack NH, Murphy GP: A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who have had extensive irradiation to the pelvis or lumbosacral area. J Urol 1983, 129:56-61.
22. Kasimis BS, Miller JB, Kaneshiro CA, Forbes KA, Moran EM, Metter GE: Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial. J Clin Oncol 1985, 3:385-392.
23. Page JP, Levi JA, Woods RL, Tattersall MN, Fox RM, Coates AS: Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma. Cancer Treatment Reports 1985, 69:105-107.
24. Torti FM, Shortliffe LD, Carter SK, Hannigan JF Jr, Aston D, Lum BL, Williams RD, Spaulding JT, Freiha FS: A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma. Cancer 1985, 56:2580-2586.
25. Benson RC Jr, Cummings K: Estramustine phosphate vs. diethylstilbestrol in the treatment of stage D prostate cancer. Prog Clin Biol Res 1989, 303:177-186.
26. Graham SD, Walker A, Cox EB, Laszlo J, Berry WR, Paulson DF: Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma. Urology 1986, 28:404-408.
27. Akaza H, Isurugi K, Oishi Y, Kitajima K, Sawamura Y, Baba S, Yoshida K, Otani M, Harada M, Gunji A: A prospective, randomized controlled study on the treatment of stage C and stage D prostatic cancer with estracyt in combination with other chemotherapeutic agents. Jpn J Clin Oncol 1988, 18:343-355.
28. Kitahara S, Fukui I, Higashi Y, Kihara K, Takeuchi S, Oshima H, Negishi T, Hosoda K, Kawai T, Ikegami S: [A randomized trial of chemotherapy of advanced prostatic cancer with ifosfamide alone versus ifosfamide, 5-fluorouracil and cisplatin (preliminary report)] [Japanese]. Nippon Gan Chiryo Gakkai Shi 1988, 23:2507-2513.
29. Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A. Harvey H, Simmonds M, White-Hershey D, Gordon R: Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 1988, 6:1456-1466.
30. McLeod DG, Murphy GP, Priore R: Comparison of megace, stilphostrol, megace plus DES, or streptozotocin in metastatic prostatic cancer in patients with hormonal failure and prior radiotherapy. Urology 1988, 32:431-436.
31. Papadopoulos I, Wand H: [Reducing the side effects of aggressive chemotherapy (cisplatin and epirubicin) with xenogenic peptides (factor AF2) in patients with hormone refractory metastatic prostate cancer. A prospective, randomized study] [German]. Onkologie 1989, 12(Suppl 3):26-31.
32. Ruff P, Derman DP, Weaving A, Bezwoda WR: Sequential hormonal therapy and sequential hormonal and chemotherapy for advanced prostatic cancer. Oncology 1989, 46:288-292.
33. Shafik A: Anal submucosal injection: a new route for drug administration in pelvic malignancies. V. Advanced prostatic cancer: results of methotrexate treatment using the anal route - preliminary study. Eur Urol 1990, 18:132-136.
34. Tveter KJ, Hagen S, Holme I, Klepp O, Kloster SE, Muri O Jr, Poulsen C, Sander S, Sivertsen S, Urnes T: A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study. Scand J Urol Nephrol 1990, 24:243-247.
35. Elomaa I, Kellokumpu-Lehtinen P, Rannikko S, Alfthan O: Hormone-resistant metastatic prostate cancer. Comparisons between estramustine phosphate and low-dose epirubicin treatments. Eur Urol 1991, 19:12-15.
36. Rangel C, Matzkin H, Soloway MS: Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer. Urology 1992, 39:577-582.
37. Francini G, Petrioli R, Manganelli A, Cintorino M, Marsili S, Aquino A, Mondillo, S: Weekly chemotherapy in advanced prostatic cancer. Br J Cancer 1993, 67:1430-1436.
38. Daliani DD, Eisenberg PD, Weems J, Lord R, Fueger R, Logothetis CJ: The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer. J Urol 1995, 153:1587-1591.
39. Breul J, Jakse G, Forster G, Lampel A, Rohani A, Hartung R. 5-fluorouracil versus folinic acid and 5-fluorouracil in advanced, hormone-resistant prostate cancer: a prospective randomized pilot trial. Eur Urol 1997, 32:280-283.
40. Brune D: Phase III trial of pirarubicin versus palliative treatment in hormone-refractory prostatic cancer [abstract]. Proc Am Soc Clin Oncol 1998, 17:316a.
41. Van Andel G, Kurth KH, Riethroek RL, Van de Velde-Muusers JA: Quality of life assessment in patients with hormone-resistant prostate cancer treated with epirubicin or with epirubicin plus medroxy progesterone acetate - Is it feasible? Eur Urol 2000, 38:259-264.
42. Dahut W, Arlen P, Gulley J, Parker C, Fedenko K, Noone M, Hamilton M: A randomized phase II trial of docetaxell plus thalidomide in androgen-independent prostate cancer [abstract]. Proc Am Soc Clin Oncol 2002, 21:183a.
43. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Kruger EA, Gubish E, Pluda JM, Reed E: A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001, 7:1888-1893.
44. Millikan R, Baez L, Banerjee T, Wade J, Edwards K, Winn R, Smith TL, Logothetis C: Randomized phase 2 trial of ketoconazole and ketoconazole/ doxorubicin in androgen independent prostate cancer. Urol Oncol 2001, 6:111-115.
45. Hervonen P, Lehtinen T, Tammela TL, Kellokumpu-Lehtinen P: A randomised dose-finding phase II study on ifosfamide in metastatic hormone-refractory prostate cancer (HRPC). J Exp Clin Cancer Res 2002, 21:177-180.
46. Tombal B, Tourani J-M, Fizazi K, Culine S, Lotz J-P, Ould Kaci M, Coppola F: Randomized phase II trial of irofulven (IROF) with or without prednisone in hormone-refractory prostate cancer (HRPC) patients (pts) [abstract]. Proc Am Soc Clin Oncol 2003, 22:407.
47. Tolcher AW, Reyno, L, Venner PM, Ernst SD, Moore M, Geary RS, Chi K, Hall S, Walsh W, Dorr A, Elsenhauer E: A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2002, 8:2530-2535.
48. Oudard S, Beuzeboc P, Dourthe LM, Voog E, Hardy-Bessard AC, Coscas I, Chauvet B: Preliminary results of a phase II randomized trial of docetaxel (D), estramustine (E), and prednisone (P) - two schedules - versus mitoxantrone (M) and prednisone in patients (pts) with hormone refractory prostate cancer (HRPC) [abstract]. Proc Am Soc Clin Oncol 2002, 21:177a.
49. Droz JP, Muracciole X, Mottet N, Ould KM, Vannetzel JM, Albin N, Culine S, Rodier JM, Misset JL, Mackenzie S, Cvitkovic E, Benoit G: Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Ann Oncol 2003, 14:1291-1298.
50. Millikan R, Thall PF, Lee SJ, Jones D, Cannon MW, Kuebler JP, Wade J III, Logothetis CJ: Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol 2003, 21:878-883.
51. Salimichokami M: Combining angiogenesis inhibitors with cytotoxic chemotherapy enhances PSA response in hormone refractory prostate cancer (HRPC), a randomized study of weekly docetaxel alone or in combination with thalidomide [abstract]. Proc Am Soc Clin Oncol 2003, 22:429.
52. Sternberg CN, Hetherington JW, Paluchowska B, Slee PH, Collette L, Debois M, Zurlo A: Randomized phase III trial of a new oral platinum, satraplatin (JM-216) plus prednisone or prednisone alone in patients with hormone refractory prostate cancer [abstract]. Proc Am Soc Clin Oncol 2003, 22:395.
53. Van Andel G, Fernandez de Moral P, Caris CT, Carpentier P, Wils J, de Bruin MJ, Witjes JA, Debruyne FM, Witjes WP: A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life. World J Urol 2003, 21:177-182.
54. Albrecht W, Van Poppel H, Horenblas S, Mickisch G, Horwich A, Serretta V, Casetta G, Marechal JM, Jones WG, Kalman S, Sylvester R: Randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. Br J Cancer 2004, 90:100-105.
55. Dimopoulos MA, Kiamouris C, Gika D, Deliveliotis C, Giannopoulos A, Zervas A, Alamanis C, Constantinidis C, Koutsilieris M: Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study. Urology 2004, 63:120-125.
56. Birch R, Kalman L, Holt L, Graham B, Wheeler B, Schwartzberg L: Randomized phase IIb trial comparing two schedules of docetaxel (D) plus estramustine (E) for metastatic hormone refractory prostate cancer (HRPC) [abstract]. Proc Am Soc Clin Oncol 2004, 23:411.
57. Eymard J-C, Joly F, Priou F, Zannetti A, Ravaud A, Kerbrat P, Mousseau M: Phase II randomized trial of docetaxel plus estramustine (DE) versus docetaxel (D) in patients (pts) with hormone-refractory prostate cancer (HRPC): a final report [abstract]. Proc. Am Soc Clin Oncol 2004, 23:406.
58. Kelly WK, Galsky MD, Small EJ, Oh W, Chen I, Smith D, Martone L: Multi-institutional trial of the epothiline B analogue BMS-247550 with or without estramustine phosphate (EMP) in patients with progressive castrate-metastatic prostate cancer (PCMPC): updated results [abstract]. Proc Am Soc Clin Oncol 2004, 23:383.
59. Lara PN, Longmate J, Stadler W, Quinn DI, Twardowski P, Martel CI, Vogelzang NJ: Angiogenesis inhibition in metastatic hormone refractory prostate cancer (HRPC): a randomized trial of two doses of the matrix metalloproteinase inhibitor (MMPI) BMS-275291 [abstract]. Proc Am Soc Clin Oncol 2004, 23:417.
60. Millikan R, Thall P, Pagliaro L, Williams D, Brown M, Logothetis C: Randomized, adaptive, phase II selection trial of four chemotherapy regimens in androgen independent prostate cancer (AIPC) [abstract]. Proc Am Soc Clin Oncol 2004, 23:395.
61. Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Roth B: Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 1999, 17:3160-3166.
62. Abratt RP, Brune D, Dimopoulos; MA, Kliment J, Breza J, Selvaggi FP, Beuzeboc P: Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol 2004, 15:1613-1621.
63. Petrylak DP, Tangen CM, Maha PH, Hussain HA, Lara PN, Jones JA, Taplin ME: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
64. Tannock IF, De Wit R, Berry WR, Horti J, Pluzanska A, Chi K, Oudard S: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
65. Iversen P, Rasmussen F, Asmussen C, Christensen IJ, Eickhoff J, Klarskov P, Larsen E, Mogensen P, Mommsen S, Rosenkilde P: Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group. J Urol 1997, 157:929-934.
66. Johansson JE, Andersson SO, Holmberg L: High-dose medroxy-progesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study. Br J Urol 1991, 68:67-73.
67. de Kernion JN, Murphy GP, Priore R: Comparison of flutamide and Emcyt in hormone-refractory metastatic prostatic cancer. Urology 1988, 31:312-317.
68. Murphy GP, Gibbons RP, Johnson DE, Prout GR, Schmidt JD, Soloway MS, Loening SA, Chu TM, Gaeta JF, Saroff J, Wajsman Z, Slack N, Scott WW: The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation. Trans Am Assoc Genitourin Surg 1979, 70:69-71.
69. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L: Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002, 168:2439-2443.
70. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999, 17:2506-2513.
71. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996, 14:1756-1764.
72. Anderström C, Eddeland A, Folmerz P, Hansson R, Milles S, Zachrisson B: Epirubicin and medroxyprogesterone acetate versus estramustine phosphate in hormone-resistant prostatic cancer: a prospective randomized study. Eur Urol 1995, 27:301-305.
73. Laurie JA, Hahn RG, Therneau TM, Patel SR, Mailliard JA, Windschitl HE, Twito DI, Morton RF, Krook JE: Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. Cancer 1992, 69:1440-1444.
74. Saxman S, Ansari R, Drasga R, Miller M, Wheeler B, McClean J, Einhorn L: Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer. A Hoosier Oncology Group Study. Cancer 1992, 70:2488-2492.
75. Murphy GP, Priore RL, Scardino PT: Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial. Urology 1988, 32:33-40.
76. Stephens RL, Vaughn C, Lane M, Costanzi J, O'Bryan R, Balcerzak SP, Levin H, Frank J, Coltman CA Jr: Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group study. Cancer 1984, 53:406-410.
77. Newling DW, Fossa SD, Tunn UW, Kurth KH, de Pauw M, Sylvester R: Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, Genitourinary Group prospective randomized phase III study (30865). J Urol 1993, 150:1840-1844.
78. Loening SA, Beckley S, Brady MF, Chu TM, Dekernion JB, Dhabuwala C, Gaeta JF, Gibbons RP, McKiel CF, McLeod DG, Pontes JE, Prout GR, Scardino PT, Schlegel JU, Schmidt JD, Scott WW, Slack NH, Soloway MS, Murphy GP: Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer. J Urol 1983, 129:1001-1006.
79. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB: Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003, 21:679-689.
80. Leaf AN, Propert K, Corcoran C, Catalano PJ, Trump DL, Harris JE, Davis TE: Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group study. Med Oncol 2003, 20:137-146.
81. Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ: Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of Intergroup Cancer and Leukemia Group B 9480. J Clin Oncol 0159, 20:3369-3375.
82. Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ, Eisenberger M: Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000, 18:1440-1450.
83. Debruyne FJ, Murray R, Fradet Y, Johansson JE, Tyrrell C, Boccardo F, Denis L, Marberger JM, Brune D, Rassweiler J, Vangeneugden T, Bruynseels J, Janssens M, De Porre P: Liarozole - a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group. Urology 1998, 52:72-81.
84. Berry W, Gregurich M, Dakhil S, Hathorn J, Asmar L: Phase II randomized trial of weekly paclitaxel (Taxol®) with or without estramustine phosphate in patients with symptomatic, hormone-refractory, metastatic carcinoma of the prostate (HRMCP) [abstract]. Proc Am Soc Clin Oncol 2001, 20:175a.
85. Carducci M, Nelson JB, Saad F, Schulman C, Dearnaley DP, Sleep DJ, Hulting SM: Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase 3 study [abstract]. Proc Am Soc Clin Oncol 2004, 23:383.
86. Small E, Rini B, Higano CS, Redfern C, Neumunaitis J, Valone F, Kylstra J: A randomized, placebo-controlled phase III trial of APC8015 in patients with androgen-independent prostate cancer (AIPCa) [abstract]. Proc Am Soc Clin Oncol 2003, 22:382.
87. Ahmann FR, Saad F, Mercier R, Huddart RA, Roberts JT, Collier M, Bettencourt L: Interim results of a phase III study of the matrix metalloprotease inhibitor prinomastat in patients having metastatic hormone refractory prostate cancer (HRPC) [abstract]. Proc Am Soc Clin Oncol 2001, 20:174a.
88. Weissbach L, Vogler H, Hofmann E, Knorr B: Palliative monochemotherapie des hormonrefrakt symptomat PCA's - ergebnisse einer prospektiven, randomisierten multizenterstudie. Urologe A 1998, 37:5.1.
89. Scher HI, Kelly WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993, 11:1566-1572.